Galderma Group Forecasts Revised as RBC Notes Robust H1, Upgraded FY26 Outlook

08:43 AM EDT, 07/30/2026 (MT Newswires) -- RBC Capital Markets revised its forecasts for Galderma Group (GALD.SW) as it noted the company's upgraded full-year 2026 guidance following a robust financial performance in the first half. The Swiss dermatology company increased its net sales growth guidance to between 19% and 21%, at constant currency, against previous expectations of 17% to 20%, according to a Wednesday note. "Galderma delivered a strong set of 1H results against high expectations and we see upgraded guidance assuming relatively conservative assumptions for 2H. With the CMD (and new mid-term targets) now expected for 1Q27, 2H is relatively quiet, but potential catalysts could include M&A activity and P2 data for Nemluvio in [chronic pruritus of unknown origin] towards year-end," the research firm said. Against this backdrop, analysts increased their EPS projections by 3% on average over the 2026 to 2030 period. Revenue and core EBITDA estimates were also upwardly adjusted over the period. The sector perform recommendation on the stock was maintained, along with the price target of 175 francs.